Advances in dopamine receptor agonists for the treatment of Parkinson’s disease

References

• Quinn N. Drug treatment of Parkinson’s disease. BMJ. 1995;310:575–579.
   PubMed Web of Science ®Google Scholar
• Stocchi F. Continuous dopaminergic stimulation and novel formulation of dopamine agonists. J Neurol. 2011;258(2):S316–S322.
   Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord. 2005 May;20(5):523–39.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–687.
   PubMed Web of Science ®Google Scholar
• Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234–241.
   PubMed Web of Science ®Google Scholar
• Bibbiani F, Costantini LC, Patel R, et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol. 2005;192:73–78.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–1491.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexolevs levodopa as initial treatment for Parkinson disease. JAMA. 2000;284:231–238.
   Google Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL¬PET study. Ann Neurol. 2003;54:93–101.
   PubMed Web of Science ®Google Scholar
• Nutt JG, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in advanced Parkinson’s disease. Trends Neurosci. 2000;23:109–115.
   PubMed Web of Science ®Google Scholar
• Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology. 2002;58(1):S1–S8.
   Google Scholar
• Hubble JP. Long-term studies of dopamine agonists. Neurology. 2002;58(1):S42–S50.
   Google Scholar
• Zhou CQ, Lou JH, Zhang YP, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014 Apr;20(4):368–376.
   PubMed Web of Science ®Google Scholar
• Malek N, Grosset DG. Medication adherence in patients with Parkinson’s disease. CNS Drugs. 2015;29:47–53.
   PubMed Web of Science ®Google Scholar
• Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate-to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010;25:2326–2332.
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77:759–766.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Hersh BP, Scott BL, et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24:2883–2895.
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double¬blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398–2404.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767–774.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and (L)-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35:174–181.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Giorgi L, Hunter B, et al. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26:1259–1265.
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513–520.
   PubMed Web of Science ®Google Scholar
• Zhou CQ, Lou JH, Zhang YP, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014 Apr;20(4):368–376.
   PubMed Web of Science ®Google Scholar
• Giladi N, Ghys L, Surmann E, et al. Effects of long-term treatment with rotigotine transdermalsystem on dyskinesia in patients with early-stage Parkinson’s disease. Parkinsonism Relat Disord. 2014 Dec;20(12):1345–1351.
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal systemover a 6-year period in patients with early-stage Parkinson’s disease. J Neural Transm (Vienna). 2013 Sep;120(9):1321–1329.
   PubMed Web of Science ®Google Scholar
• Elmer LW, Surmann E, Boroojerdi B, et al. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: a prospective, open label extension study. Parkinsonism Relat Disord. 2012;18:488–493.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double blind, placebocontrolledtrial in Parkinson disease. Arch Neurol. 2007;64:676–682.
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276.
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004;21:687–709.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Ray Chadury K, Garcia Riuz Pedro J, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease – clinical practice recommendations. Parkinsonisms Relat Disord. 2015;21(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• Poltaski L, Edwards H, Todd A, et al. Ultrasound treatment of cutaneous side effects of infused apomorphine: a randomized controlled pilot study. Mov Disord. 2009;24:115–118.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord. 1993;8(2):165–170.
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr., Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392.
   PubMed Web of Science ®Google Scholar
• Vernalis Pharmaceuticals Inc. Data on file. Study APO301. 2009.
   Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL Jr., et al.; The APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 2007;13(2):93–100.
   PubMed Web of Science ®Google Scholar
• Tschopp L, Salazar Z, Gomez Botello MT, et al. Impulse control disorder and piribedil: report of 5 cases. Clin Neuropharmacol. 2010;33(1):11–13.
   PubMed Web of Science ®Google Scholar
• Giugni JC, Tschopp L, Escalante V, et al. Dose-dependentimpulse control disorders in piribedil overdose. Clin Neuropharmacol. 2012;35(1):49–50.
   PubMed Web of Science ®Google Scholar
• Micheli F, Giugni J, De Arco Espinosa M, et al. Piribedil and pathological gambling in six parkinsonian patients. Arq Neuropsiquiatr. 2015;73(2):115–118.
   PubMed Web of Science ®Google Scholar
• Eggert K, Öhlwein C, Kassubek J, et al. Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014;37(4):116–122.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al.; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26(1):90–99.
   PubMed Web of Science ®Google Scholar
• Ghys L, Surmann E, Whitesides J, et al. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post-hoc analysis of RECOVER patients who were symptomatic at baseline. Expert OpinPharmacother. 2011;12:1985–1998.
   PubMed Web of Science ®Google Scholar
• Kassubek J, Ray Chadury K, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurology. 2014;14:42.
   PubMed Web of Science ®Google Scholar
• Hirano M, Isono C, Sakamaoto H, et al. Rotigotine transdermal patch improves swallowing in dysphagic patients with Parkinson’s disease. Dysphagia. 2015;30(4):452–456.
   PubMed Web of Science ®Google Scholar
• Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine patch in patients with Parkinson’s disease presenting with non-motor symptoms ¬results of a double blind, randomized, placebo controlled trial. Eur J Neurol. 2015;22:1400–1407.
   PubMed Web of Science ®Google Scholar
• Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on non motor symptoms of Parkinson’s disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31:261–266.
   PubMed Web of Science ®Google Scholar
• Buchwald B, Angersbach D, Jost WH. Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy. Fortschr Neurol Psychiatr. 2007 Apr;75(4):236–241.
   PubMed Web of Science ®Google Scholar
• Ray Chauduri K, Martin¬Martinez P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012 Jan;19(1):105–113.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al.; EASE¬PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–1115.
   PubMed Web of Science ®Google Scholar
• Antonini A, Barone P, Ceravolo R, et al. Role of pramipexole in the management of Parkinson’s disease. CNS Drugs. 2010;24(10):829–841.
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo¬controlled trial. Lancet Neurol. 2010;9(6):573–580.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–S80.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Todoriva A, Ray Chadury K. Subcutaneous apomorphine and non¬motor symptoms in Parkinson’s disease. Parkin Relat Disord. 2013;19:1073–1078.
   PubMed Web of Science ®Google Scholar
• Martinez¬Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real-life study of non-motor effect. J Parkininson’s Dis. 2011;1:197–203.
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33:490–493.
   PubMed Web of Science ®Google Scholar
• Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord. 1996;11:729–732.
   PubMed Web of Science ®Google Scholar
• Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2:1451–1453.
   PubMed Web of Science ®Google Scholar
• Alegret M, Valldeoriola F, Martì M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord. 2004;19:1463–1469.
   PubMed Web of Science ®Google Scholar
• Ellis C, Lemmens G, Parkes DJ, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications of oral treatment. Parkinsonism Relat Disord. 1997;3:103–107.
   PubMedGoogle Scholar
• Van Laar T, Postuma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson’s disease and pre¬existing visual hallucinations. Parkinsonism Relat Disord. 2010;16:71–72.
   PubMed Web of Science ®Google Scholar
• Magennis B, Cashell A, O’Brien D, et al. An audit of apomorphine in the management of complex idiopathic Parkinson’s disease in Ireland. Mov Disord. 2012;27(Suppl 1):S44.
   Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23:1130–1136.
   PubMed Web of Science ®Google Scholar
• Lefaucheur R, Berthelot L, Senant J, et al. Acute genital pain during non¬motor fluctuations improved by apomorphine. Mov Disord. 2013;28:5687–5688.
   Web of Science ®Google Scholar
• Factor SA, Brown DL, Molho ES. Sucutaneousapomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000;15:167–169.
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, Maraganore DM, Ahlskog JE, et al. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson’s disease. Mov Disord. 1998 Sep;13(5):782–787.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol. 2013 Nov;20(11):1445–1450.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled dry powder apomorphine (VR040) for ‘off ‘ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013 Sep;128(3):166–171.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled apomorphine in patients with ‘on-off’ fluctuations: a randomized, double-blind, placebo¬controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3(1):31–37.
   PubMedGoogle Scholar
• Montastruc JL, Rascol O, Senard JM, et al. Sublingual apomorphine in Parkinson’s disease: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1991;14:432–437.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Webster R, Bovingdon M, et al. Sublingual apomorphine in the treatment of Parkinson’s disease complicated by motor fluctuations. Clin Neuropharmacol. 1991;14:556–561.
   PubMed Web of Science ®Google Scholar
• Ondo W, Hunter C, Almaguer M, et al. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson’s disease. Clin Neuropharmacol. 1999;22:1–4.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Dubow J, Dzyngel B, et al. Efficacy of sublingual apomorphine (APL‐130277) for the treatment of “off” episodes in patients with Parkinson’s disease. Mov Disord. 2015;30(Suppl 1):233.
   Google Scholar
• Available from: www.clincaltrials.gov. Protocol number: NCT02469090.
   Google Scholar
• Laffleur F, Wagner J, Barthelmes J. A potential tailor¬made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson’s disease? Future Med Chem. 2015;7(10):1225–1232.
   PubMed Web of Science ®Google Scholar
• Rabinak AC, Niremberg JM. Dopamine agonist withdrawal syndrome in Parkinson’s disease. Arch Neurol. 2010;67(1):58–63.
   PubMedGoogle Scholar
• Niremberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013;30:587–592.
   PubMed Web of Science ®Google Scholar
• Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84:130–135.
   PubMed Web of Science ®Google Scholar
• Limotai N, Oyama G, Go C, et al. Addiction-like manifestations and Parkinson’s disease: a large single-center 9-year experience. Int J Neurosci. 2012;122:145–153.
   PubMed Web of Science ®Google Scholar
• Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:1051–1052.
   PubMed Web of Science ®Google Scholar
• Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–333.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza M, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–595.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson’s disease: the NMS quest study. Mov Disord. 2006;21:916–923.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioraldisturbances in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:202–207.
   PubMed Web of Science ®Google Scholar
• Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospectivecohort study of impulse control disorders in Parkinson’sdisease. Mov Disord. 2013;28:327–330.
   PubMed Web of Science ®Google Scholar
• Molina JA, Sáinz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson’sdisease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15:869–872.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:261–265.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord. 1999;14:836–838.
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Erro R, et al. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: report of 2 cases. Parkinsonism Relat Disord. 2013;19:483–484.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969–973.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14:28–32.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:261–265.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–595.
   PubMed Web of Science ®Google Scholar
• Rizos A, Sauerbier A, Antonini A, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23(8):1255–1261.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):840–844.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus) epidemiology and management. CNS Drugs. 2002;16(3):165–174.
   PubMed Web of Science ®Google Scholar
• Cannas A, Solla P, Floris G, et al. Reversible Pisa syndrome in Parkinson’s disease during dopaminergic treatment with Pergolide: a case report. Clin Neuropharmacol. 2005;28:252.
   PubMed Web of Science ®Google Scholar
• Garbarin M, Antonini A, Moretto G, et al. Pisa syndrome without neuroleptic exposure in a patient with Parkinson’s disease: case report. Mov Disord. 2006;21:270–273.
   PubMed Web of Science ®Google Scholar
• Galati S, Möller JC, Städler C. Ropinirole ¬induced Pisa syndrome in Parkinson disease. Clin Neuropharmacol. 2014;37(2):58–59.
   PubMed Web of Science ®Google Scholar
• Cannas A, Solla P, Floris G, et al. Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy. J Neurol. 2009;256:390–395.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Furnari A, Buscone S, et al. Pisa syndrome in Parkinson’s disease: clinical, electromyographic, and radiological characterization. Mov Disord. 2012;27(2):227–235.
   PubMed Web of Science ®Google Scholar
• Mokhles MM, Trifiro G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65:358–364.
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’Aniello S, Brophy JM, et al. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21:34–41.
   PubMed Web of Science ®Google Scholar
• Hsieh PH, Hsiao FY. Risk of heart failure associated with dopamine agonists: a nested case¬control study. Drugs Aging. 2013;30(9):739–745.
   PubMed Web of Science ®Google Scholar
• Perez-¬Lloret S, Rey MV, Crispo J, et al. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf. 2014;13(3):351–360.
   PubMed Web of Science ®Google Scholar
• Apraxine M, Pasuqet A, Jeanjean A. Pramipexole-induced reversible heart failure. Mov Disord Clin Pract. 2014;1(4):381–382.
   PubMedGoogle Scholar
• Chondrogiorgi M, Tatsioni A, Reichmann H, et al. Dopamine agonist monotherapy in Parkinson’s disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol. 2014;21:433–440.
   PubMed Web of Science ®Google Scholar
• Visanji NP, Fox SH, Johnston T, et al. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Neurobiol Dis. 2009;35:184–192.
   PubMed Web of Science ®Google Scholar
• Guigoni C, Aubert I, Li Q, et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord. 2005;11:S25–S29.
   PubMed Web of Science ®Google Scholar
• Simms SL, Huettner DP, Kortagere S. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson’s disease. Neuropharmacology. 2016;100:106–115.
   PubMed Web of Science ®Google Scholar
• Van Kampen JM, Eckman CB. Dopamine D3 receptor agonist delivery to a model of Parkinson’s disease restores the nigrostriatal pathway and improves locomotorbehavior. J Neurosci. 2006;26:7272–7280.
   PubMed Web of Science ®Google Scholar
• Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson’s disease. Lancet. 2002;360:1767–1769.
   PubMed Web of Science ®Google Scholar
• Cazorla M, Jung Kang U, Kellendonk C. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease. Mov Disord. 2015;30(7):895–903.
   PubMed Web of Science ®Google Scholar